What Researchers Did
Researchers conducted a systematic review to evaluate the effectiveness and adverse effects of vasodilators and other vasoactive substances for idiopathic sudden sensorineural hearing loss (ISSHL) by analyzing three randomized controlled trials involving 189 participants.
What They Found
This systematic review analyzed three randomized controlled trials involving 189 participants. Due to significant differences in the types, dosages, and durations of vasodilators used, a meta-analysis was not possible. The individual analysis of these studies did not provide clear evidence of benefit for vasodilators or vasoactive substances in improving hearing for idiopathic sudden sensorineural hearing loss.
What This Means for Canadian Patients
Canadian patients experiencing sudden sensorineural hearing loss should be aware that current evidence does not clearly support the use of vasodilators or vasoactive substances for improving their hearing. They should discuss treatment options with their healthcare providers, focusing on therapies with established efficacy.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
A major limitation was the inability to perform a meta-analysis due to significant heterogeneity among the included trials regarding the type, dosage, and duration of vasodilators used.